CompletedPHASE1, PHASE2NCT02545907

A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis

Studying AL amyloidosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University College, London
Principal Investigator
Ashutosh Wechalekar, Dr
University College London, National Amyloidosis Centre
Intervention
Carfilzomib(drug)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
2017 – 2019

Study locations (14)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02545907 on ClinicalTrials.gov

Other trials for AL amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for AL amyloidosis →

← Back to all trials